300347 泰格医药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,832,8013.48%7,384,0397,085,4715,213,5383,192,279
减:营业总成本6,312,64512.52%5,554,1255,156,5443,637,7652,420,862
    其中:营业成本4,959,60613.72%4,535,5114,277,0082,942,8831,678,036
               财务费用99,902162.44%(108,324)(158,124)(216,363)88,052
               资产减值损失(38,961)-3,205.59%(29,725)(2,416)(12,915)5,414
公允价值变动收益42,256-108.42%352,771535,8571,815,3901,137,889
投资收益433,816160.33%338,175102,751312,283283,773
    其中:对联营企业和合营企业的投资收益198,507534.80%105,18339,76314,348(3,508)
营业利润1,009,42051.93%2,486,9412,582,3993,696,9672,222,312
利润总额1,003,21550.98%2,488,5332,585,3773,684,5662,218,707
减:所得税费用198,159-8.53%338,606313,652292,864189,707
净利润805,05679.77%2,149,9272,271,7253,391,7022,029,001
减:非控股权益(82,834)-294.05%125,077265,173517,539279,226
股东净利润887,890119.15%2,024,8502,006,5522,874,1631,749,775

市场价值指针
每股收益 (元) *1.040121.28%2.3402.3203.3102.200
每股派息 (元) *0.126-58.00%0.5680.5500.5000.300
每股净资产 (元) *24.3421.86%24.10222.44720.77418.474
审计意见 #标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容